Day: June 5, 2023

Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares

Written by Customer Service on . Posted in Public Companies.

Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP, representing 45.3% of its share capital and 62.2% of its theoretical voting rights, at a price of 35.00 Euros per share. Certain minority shareholders, representing 19.0% of the share capital and 13.07% of the theoretical voting rights of BIOCORP, have committed to transfer shares to Novo Nordisk upon completion of the acquisition of BIO JAG’s stake.The proposed transaction would be followed by a mandatory simplified tender offer launched by Novo Nordisk on all remaining outstanding BIOCORP securities and, if the legal requirements are met, a mandatory squeeze-out of the remaining shareholders and delisting of BIOCORP. Bagsværd, Denmark and Issoire, France, 5 June, 2023 – Novo Nordisk A/S and BIOCORP...

Continue reading

Lleida.net reaches a milestone with the issuance of the 100 millionth certified e-mail using its proprietary method

Written by Customer Service on . Posted in Public Companies.

MADRID, Spain, June 05, 2023 (GLOBE NEWSWIRE) — Lleida.net (OTC.US) (ALLLN.PA) (LLN.MA) issued its 100 millionth certified email last week, a milestone in the company’s history. Since launching this service in 2012, Lleida.net has become one of the world’s leading providers in the registered electronic notification, signature and contracting industry. This milestone follows a decade of steady, exponential growth, with the company systematically increasing its market reach and penetration. Lleida.net’s service portfolio has shown sustained growth in recent years. The company reached its first million certified emails in 2016. Subsequently, the number of registered emails issued increased to ten million in 2018, 25 million in 2021 and, finally, 50 million in 2022. Growth has been steady and rapid, reaching 100 million...

Continue reading

VERSES, DENTONS US and SPATIAL WEB FOUNDATION To Release Industry Report Titled “A Path to Global AI Governance”

Written by Customer Service on . Posted in Public Companies.

Figure 1 The Road to Autonomy – Executive Summary VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — VERSES AI Inc.  (CBOE CANADA:VERS) (OTCQX:VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in the next generation of artificial intelligence (“AI”), announces the release on June 8, 2023 of an AI industry report titled “THE ROAD TO AUTONOMY: A Path To Global AI Governance”.  The report combines the legislative expertise from Dentons, the world’s largest multinational law firm, and the AI acumen of VERSES with the guidance on technical standards from the Spatial Web Foundation to provide an in-depth analysis of the legal and key legislative trends from across the world on the state of AI regulation and recommendations for a path forward for government regulation of...

Continue reading

Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial

Written by Customer Service on . Posted in Public Companies.

New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, Texas Enrolment now open to patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and most deadly primary brain cancer SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) — Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only clinical stage cell therapy company on the ASX, is pleased to announce activation of a Phase 1B clinical trial in patients with recurrent and/ or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company’s first in class CLTX CAR T cell therapy. (ClinicalTrials.gov Identifier: NCT05627323) The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David’s...

Continue reading

Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role

Written by Customer Service on . Posted in Public Companies.

NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role. Dr. Krause was formerly Deputy Director of the Office of Vaccines Research and Review at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) and is an internationally recognized expert on development and regulatory aspects of biologic products. Dr. Krause will advise the company on its regulatory strategies related to broadening out the remestemcel-L platform, including the ground-breaking treatment for steroid-refractory acute graft versus host disease (SR-aGVHD), inflammatory bowel disease and...

Continue reading

Patriot Provides Operational Update on the Work Programs at the Corvette Property, Quebec, Canada

Written by Customer Service on . Posted in Public Companies.

Summary: The Province of Quebec has requested exploration companies to cease field activities due to very high forest fire risk over a large part of the province which includes the Corvette Property. The Company has ceased field exploration operations but will continue to process core from the drill holes completed to date and advance the camp construction activities in respect of the government requirements. The Company will continue to monitor the situation and provide further updates as it evolves. VANCOUVER, British Columbia and SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) — Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) provides this update on its work programs and the impact of the current forest fire situation in Quebec the Company’s operations. The Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.